Lenalidomide, Adriamycin and Dexamethason (RAD) in Relapsed and Refractory Multiple Myeloma: Final Results from a Phase I/II Trial of "Deutsche Studiengruppe Multiples Myelom".

被引：0
|
作者：
Gerecke, Christian [1 ]
Knop, Stefan [2 ]
Topp, Max S. [2 ]
Liebisch, Peter [3 ]
Vollmuth, Christina [2 ]
Platzbecker, Uwe [4 ]
Maeder, Uwe [5 ]
Einsele, Hermann [6 ]
Bargou, Ralf C. [2 ]
机构：
[1] Helios Hosp Berlin Buch, Berlin, Germany
[2] Univ Wurzburg, Med Ctr, Wurzburg, Germany
[3] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[4] Univ Hosp Dresden, Dresden, Germany
[5] Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[6] Univ Wurzburg, Dept Hematol Oncol, Wurzburg, Germany
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：961 / 961
页数：1
相关论文
共 50 条
  • [41] Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): Final results of a multicenter phase 1 trial.
    Richardson, Paul G.
    Jagannath, S.
    Avigan, D. E.
    Alsina, M.
    Schlossman, R. L.
    Mazumder, A.
    Munshi, N. C.
    Ghobrial, I.
    Doss, D.
    McKenney, M. L.
    Farrell, M. G.
    Warren, D. L.
    Lunde, L. E.
    Gourley, B.
    Vaccaro, S.
    Delaney, C.
    Pountney, S.
    Mitsiades, C. S.
    Hideshima, T.
    Byrne, C.
    Knight, R.
    Birner, A.
    Myers, T.
    Weller, E.
    Anderson, K. C.
    BLOOD, 2006, 108 (11) : 124A - 124A
  • [42] Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma - Final time-to-event results from the SUMMIT trial
    Richardson, PG
    Barlogie, B
    Berenson, J
    Singhal, S
    Jagannath, S
    Irwin, DH
    Rajkumar, SV
    Srkalovic, G
    Alsina, M
    Anderson, KC
    CANCER, 2006, 106 (06) : 1316 - 1319
  • [43] Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
    Jakubowiak, Andrzej J.
    Richardson, Paul G.
    Zimmerman, Todd
    Alsina, Melissa
    Kaufman, Jonathan L.
    Kandarpa, Malathi
    Kraftson, Stephanie
    Ross, Charles W.
    Harvey, Colleen
    Hideshima, Teru
    Sportelli, Peter
    Poradosu, Enrique
    Gardner, Lesa
    Giusti, Kathy
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (04) : 472 - 480
  • [44] A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients
    Berenson, James R.
    Jennifer, To
    Spektor, Tanya M.
    Turner, Carley
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Stampleman, Laura V.
    Moss, Robert A.
    Bessudo, Alberto
    Patel, Ravindranath
    Lim, Stephen
    Vescio, Robert
    BLOOD, 2018, 132
  • [45] A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
    Berenson, James R.
    Limon, Andrea
    Rice, Stephanie
    Safaie, Tahmineh
    Boccia, Ralph
    Yang, Honghao
    Moezi, Mehdi
    Lim, Stephen
    Schwartz, Gary
    Eshaghian, Shahrooz
    Brobeck, Matthew
    Swift, Regina
    Eades, Benjamin M.
    Bujarski, Sean
    Sebhat, Yohana
    Ray, Rudra
    Kim, Susanna
    Del Dosso, Ashley
    Vescio, Robert
    TARGETED ONCOLOGY, 2024, 19 (03) : 343 - 357
  • [46] Revlimid, Bendamustine and Prednisolone (RBP) in relapsed/refractory multiple myeloma: final results of a phase II clinical trial OSHO - #077
    Poenisch, W.
    Beck, J.
    Heyn, S.
    Schliwa, T.
    Lange, T.
    Andrea, M.
    Jentzsch, M.
    Schwind, S.
    Bill, M.
    Mohren, M.
    Hoffmann, F. -A
    Kreibich, U.
    Glaeser, D.
    Uhlig, J.
    Muegge, L. -O
    Kragl, B.
    Zehrfeld, T.
    Schwarzer, A.
    Winkelmann, C.
    Edelmann, T.
    Niederwieser, D. W.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 204 - 204
  • [47] A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results
    von Tresckow, Bastian
    Boell, Boris
    Eichenauer, Dennis A.
    Peine, Denissa
    Knop, Stefan
    Goebeler, Mariele
    Chemnitz, Jens M.
    Hallek, Michael
    Engert, Andreas
    Huebel, Kai
    BLOOD, 2011, 118 (21) : 1696 - 1696
  • [48] Combination of Bendamustine, Lenalidomide, and Dexamethasone In Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of a Phase I Clinical Trial
    Lentzsch, Suzanne
    O'Sullivan, Amy
    Kennedy, Ryan
    Gill, Navkiranjit
    Andreas, Carrie
    Gardner, Diane
    Lalo, Silvana
    Burt, Steve
    Redner, Robert L.
    Volkin, Robert
    Roodman, David
    Mapara, Markus Y.
    Viverette, Frank
    Agha, Mounzer
    Zonder, Jeffrey A.
    BLOOD, 2010, 116 (21) : 435 - 435
  • [49] Lenalidomide in combination with Bendamustine and Prednisolone (RBP) in patients with refractory or relapsed multiple myeloma. Preliminary results of a phase I clinical trial
    Poenisch, W.
    Heyn, S.
    Wagner, I
    Mohren, M.
    Hoffmann, F. A.
    Schueler, F.
    Al-Ali, H. K.
    Jaekel, N.
    Niederwieser, D.
    ONKOLOGIE, 2010, 33 : 156 - 156
  • [50] Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    Reece, Donna E.
    Masih-Khan, Esther
    Khan, Arooj
    Dean, Saima
    Anglin, Peter
    Chen, Christine
    Kukreti, Vishal
    Mikhael, Joseph R.
    Trudel, Suzanne
    BLOOD, 2009, 114 (22) : 744 - 744
12345